alexa Darwinian Principles toward Multidrug-Resistant Cancer Cells | OMICS International
ISSN: 1920-4159
Journal of Applied Pharmacy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Darwinian Principles toward Multidrug-Resistant Cancer Cells

Mehmet Varol*1,2

1Department of Biology, Faculty of Science, Yunusemre Campus, Anadolu University, Eskisehir TR26470, Turkey

2Department of Molecular Biology and Genetics, Kotekli Campus, Mugla Sitki Kocman University, Mugla TR 48000, Turkey

*Corresponding Author:
Mehmet Varol
Department of Molecular Biology and Genetics
Faculty of Science
Kotekli Campus
Mugla Sitki Kocman University
Mugla TR48000, Turkey
Tel: 0090-252-2113132
Fax: +90-252-2119280
E-mail: [email protected]

Received date: May 24, 2016; Accepted date: May 26, 2016; Published date: May 30, 2016

Citation: Varol M (2016) Darwinian Principles toward Multidrug-Resistant Cancer Cells. J App Pharm 8:e111. doi:10.4172/1920-4159.1000e111

Copyright: © 2016 Varol M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Applied Pharmacy

Introduction

As the conventional treatment strategies, systemic cancer chemotherapies have been still recommended to treat wide variety of cancer diseases [1]. To ensure the maximum clinical benefits by destruction of the greatest possible number of cancer cells, the clinicians prescribe the maximum tolerated dose of chemotherapy [2-4]. However, this treatment method leads to some side effects for patients such as systemic toxicity, drug resistance and potential longterm side effects [5-7]. The attention and efforts of scientists had been, therefore, drawn to develop new chemotherapy treatment strategies to improve clinical benefits and reduce the side effects by taking into consideration the impact of dose intensity, dose density, and treatment duration [3].

Metronomic therapy had been proposed as the one of the alternative treatment modalities to reduce side effects and apply greater cumulative doses of chemotherapeutic agents [8]. This alternative strategy has been performed by using low dose conventional chemotherapeutic agents with no prolonged drug-free breaks to kill maximum tumor cells [8]. However, the oncologists generally have faced the developing drug resistant cancer cell populations as the most important and major problem of classical, metronomic or molecularly targeted chemotherapy [9].

Some rational hypothesis for the evolving chemo-resistant cancer cell populations have been proposed by dividing into two major categories as the developing resistance due to the intrinsic factors including phenotypic drug resistance (increased DNA repair and expression of p-glycoprotein etc.), tumor cytokinetics (undergoing mitosis despite the anti-mitotic therapeutics) and evaluation (Darwinian selection of resistant population against chemotherapeutics), and the developing chemo-resistant populations by extrinsic factors including poor perfusion, increased intratumoral interstitial pressure, hypoxia, extracellular acidosis and protective effects of the tumor-associated mesenchymal cells [9]. On the other hand, it had been also established that environmentally or phenotypically mediated resistant cancer cells are present before the chemotherapeutic treatment, and the applied chemotherapy might lead to a Darwinian selection for the chemo-resistant cell populations due to the genetically unstable and heterogeneous features of cancer cell populations [10-13]. By consideration the Darwinian principles, different types of populations and cells compete with each other for space and substrate within the heterogeneous structure of a tumor. Thus, the chemo-resistant cells or populations come forward and excessively proliferate due to the more space and adequate substrate when the applied chemotherapeutics kill the chemo-sensitive cells and populations [10,14,15].

Similarly, the occurrence of chemo-sensitive cancer cells in the micro-environment limit to the proliferation and expansion of chemoresistant cell population due to the high metabolic cost of the chemoresistant phenotype which needs synthesis, maintenance, and operation of membrane extrusion pumps [10]. This Darwinian thought about the dynamics of tumor microenvironment have created the eco-evaluation-based cancer treatment strategy (adaptive therapy) to block the evolving of chemo-resistant populations and to maximize time to progression rather than reduction in tumor size [13,16-19].

Enriquez-Navas and colleagues have recently published a paper which provides significant evidences that showed the advantages of adaptive therapy (low dose, frequent chemotherapy) as a better alternative to conventional high dose chemotherapy [10]. Their study provide that optimized adaptive cancer therapy either limit to the tumor size and the proliferation of drug resistant population. So the therapeutics could preserve the effectiveness on the cancer cell population and indicate less damage the surrounding tissues. Additionally, the tumor size may be reduced with the approaches of combinational chemotherapy applications by using anti-angiogenic drugs and immune system modulators [20], and the natural compounds which are cancer selective but low cytotoxic might be gain more importance with this Darwinian touch to conventional chemotherapeutic strategies. Consequently, the new strategies seems to be completely less aggressive despite the offensive manner of the past treatment modalities, and the side effects are not acceptable anymore for the clinicians and patients.

Acknowledgement

We would like to thank all researchers who have contributed to develop alternative cancer treatment modalities with their precious studies.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8040
  • [From(publication date):
    July-2016 - Dec 19, 2017]
  • Breakdown by view type
  • HTML page views : 7940
  • PDF downloads : 100
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version